1. Home
  2. XLO vs IPSC Comparison

XLO vs IPSC Comparison

Compare XLO & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XLO
  • IPSC
  • Stock Information
  • Founded
  • XLO 2016
  • IPSC 2019
  • Country
  • XLO United States
  • IPSC United States
  • Employees
  • XLO N/A
  • IPSC N/A
  • Industry
  • XLO Biotechnology: Pharmaceutical Preparations
  • IPSC Medicinal Chemicals and Botanical Products
  • Sector
  • XLO Health Care
  • IPSC Health Care
  • Exchange
  • XLO Nasdaq
  • IPSC Nasdaq
  • Market Cap
  • XLO 35.7M
  • IPSC 42.2M
  • IPO Year
  • XLO 2021
  • IPSC 2021
  • Fundamental
  • Price
  • XLO $0.72
  • IPSC $0.48
  • Analyst Decision
  • XLO Buy
  • IPSC Strong Buy
  • Analyst Count
  • XLO 2
  • IPSC 5
  • Target Price
  • XLO $3.00
  • IPSC $3.33
  • AVG Volume (30 Days)
  • XLO 438.3K
  • IPSC 730.8K
  • Earning Date
  • XLO 08-14-2025
  • IPSC 11-04-2025
  • Dividend Yield
  • XLO N/A
  • IPSC N/A
  • EPS Growth
  • XLO N/A
  • IPSC N/A
  • EPS
  • XLO N/A
  • IPSC N/A
  • Revenue
  • XLO $15,001,000.00
  • IPSC $114,128,000.00
  • Revenue This Year
  • XLO $982.12
  • IPSC $1,589.94
  • Revenue Next Year
  • XLO N/A
  • IPSC N/A
  • P/E Ratio
  • XLO N/A
  • IPSC N/A
  • Revenue Growth
  • XLO 536.45
  • IPSC 5491.77
  • 52 Week Low
  • XLO $0.62
  • IPSC $0.34
  • 52 Week High
  • XLO $1.70
  • IPSC $1.86
  • Technical
  • Relative Strength Index (RSI)
  • XLO 57.13
  • IPSC 36.76
  • Support Level
  • XLO $0.67
  • IPSC $0.46
  • Resistance Level
  • XLO $0.76
  • IPSC $0.55
  • Average True Range (ATR)
  • XLO 0.04
  • IPSC 0.04
  • MACD
  • XLO 0.00
  • IPSC -0.01
  • Stochastic Oscillator
  • XLO 64.17
  • IPSC 14.69

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Share on Social Networks: